Faculty Profiles - FUJIWARA Toshiyoshi

Papers - FUJIWARA Toshiyoshi

Division display 1,501 - 1,520 of about 1,586 ／ All the affair displays >>

岡山大学病院における胃癌に対するダビンチS(da Vinci S surgical system)によるロボット支援腹腔鏡下手術の導入

香川俊輔, 西崎正彦, 宇野太, 岸本浩行, 白川靖博, 永坂岳司, 野間和広, 田辺俊介, 近藤喜太, 横道直佑, 森川達也, 佃和憲, 浅野博昭, 内藤稔, 藤原俊義

岡山医学会雑誌 123 ( 2 ) 167 - 167 2011.8

悪性リンパ腫合併胸部食道癌症例の治療経験

横道直佑, 白川靖博, 野間和広, 田辺俊介, 森川達也, 近藤喜太, 櫻間教文, 岸本浩行, 宇野太, 永坂岳司, 西崎正彦, 香川俊輔, 藤原俊義

岡山医学会雑誌 123 ( 2 ) 166 - 166 2011.8

胃癌に対する腹腔鏡下手術の新たな考え方と工夫肝十二指腸間膜左側アプローチによるNo.12a郭清

西崎正彦, 香川俊輔, 宇野太, 岸本浩行, 合地明, 藤原俊義

日本消化器外科学会総会 66回 276 - 276 2011.7

当科における食道胃接合部領域の食道癌に対する治療

白川靖博, 横道直佑, 田辺俊介, 野間和広, 櫻間教文, 山辻知樹, 猶本良夫, 羽井佐実, 藤原俊義

日本消化器外科学会総会 66回 774 - 774 2011.7

消化器外科周術期における栄養療法の進歩 FITMATEを用いて呼吸商から基礎代謝を測定し、術後栄養管理に利用する新しい試み

櫻間教文, 西川みか, 平松聡, 繁光薫, 山辻知樹, 猶本良夫, 田辺俊介, 野間和広, 白川靖博, 藤原俊義

日本消化器外科学会総会 66回 263 - 263 2011.7

当科における胃管作成および再建術の工夫

野間和広, 白川靖博, 横道直佑, 田辺俊介, 櫻間教文, 山辻知樹, 羽井佐実, 猶本良夫, 藤原俊義

日本消化器外科学会総会 66回 499 - 499 2011.7

同時多発性胃癌術後の残胃癌に関する検討

香川俊輔, 宇野太, 岸本浩行, 西崎正彦, 白川靖博, 永坂岳司, 野間和広, 近藤喜太, 田辺俊介, 藤原俊義

日本消化器外科学会総会 66回 297 - 297 2011.7

岡山大学外科研修マネージメントセンター医局を超えた外科研修教育の取り組み

菊地覚次, 香川俊輔, 篠浦先, 野間和広, 松岡順治, 土井原博義, 八木孝仁, 佐野俊二, 三好新一郎, 藤原俊義

日本消化器外科学会総会 66回 185 - 185 2011.7

体内鉄コントロールによるN-cadheinの発現低下が癌細胞の浸潤・転移能にどのような影響を与えるかについての検討 Reviewed

西谷正史, 野間和広, 大原利章, 友野靖子, 田邊俊介, 白川靖博, 藤原俊義

日本外科学会雑誌 112 ( 臨増1-2 ) 595 - 595 2011.5

体内鉄コントロールを利用したBevacizumabの新規治療法 Reviewed

大原利章, 野間和広, 友野靖子, 西谷正史, 田辺俊介, 田澤大, 白川靖博, 藤原俊義

日本外科学会雑誌 112 ( 臨増1-2 ) 771 - 771 2011.5

食道癌転移診断におけるPET-CT偽陽性症例の検討 Reviewed

山辻知樹, 関亮太, 木下真一郎, 深澤拓也, 林次郎, 繁光薫, 吉田和弘, 森田一郎, 山田英司, 西谷正史, 大原利章, 田邊俊介, 藤原康宏, 櫻間教文, 野間和広, 高岡宗徳, 白川靖博, 松岡順治, 羽井佐実, 藤原俊義, 猶本良夫

日本外科学会雑誌 112 ( 臨増1-2 ) 837 - 837 2011.5

Preclinical Evaluation of Telomerase-Specific Oncolytic Virotherapy for Human Bone and Soft Tissue Sarcomas Reviewed

Tsuyoshi Sasaki, Hiroshi Tazawa, Jo Hasei, Toshiyuki Kunisada, Aki Yoshida, Yuuri Hashimoto, Shuya Yano, Ryosuke Yoshida, Futoshi Uno, Shunsuke Kagawa, Yuki Morimoto, Yasuo Urata, Toshifumi Ozaki, Toshiyoshi Fujiwara

CLINICAL CANCER RESEARCH 17 ( 7 ) 1828 - 1838 2011.4

Language：English Publishing type：Research paper (scientific journal) Publisher：AMER ASSOC CANCER RESEARCH

Purpose: Tumor-specific replication-selective oncolytic virotherapy is a promising antitumor therapy for induction of cell death in tumor cells but not of normal cells. We previously developed an oncolytic adenovirus, OBP-301, that kills human epithelial malignant cells in a telomerase-dependent manner. Recent evidence suggests that nonepithelial malignant cells, which have low telomerase activity, maintain telomere length through alternative lengthening of telomeres (ALT). However, it remains unclear whether OBP-301 is cytopathic for nonepithelial malignant cells. Here, we evaluated the antitumor effect of OBP-301 on human bone and soft tissue sarcoma cells.
Experimental Design: The cytopathic activity of OBP-301, coxsackie and adenovirus receptor (CAR) expression, and telomerase activity were examined in 10 bone (OST, U2OS, HOS, HuO9, MNNG/HOS, SaOS-2, NOS-2, NOS-10, NDCS-1, and OUMS-27) and in 4 soft tissue (CCS, NMS-2, SYO-1, and NMFH-1) sarcoma cell lines. OBP-301 antitumor effects were assessed using orthotopic tumor xenograft models. The fiber-modified OBP-301 (termed OBP-405) was used to confirm an antitumor effect on OBP-301-resistant sarcomas.
Results: OBP-301 was cytopathic for 12 sarcoma cell lines but not for the non-CAR-expressing OUMS27 and NMFH-1 cells. Sensitivity to OBP-301 was dependent on CAR expression and not on telomerase activity. ALT-type sarcomas were also sensitive to OBP-301 because of upregulation of human telomerase reverse transcriptase (hTERT) mRNA following virus infection. Intratumoral injection of OBP-301 significantly suppressed the growth of OST and SYO-1 tumors. Furthermore, fiber-modified OBP-405 showed antitumor effects on OBP-301-resistant OUMS-27 and NMFH-1 cells.
Conclusions: A telomerase-specific oncolytic adenovirus is a promising antitumor reagent for the treatment of bone and soft tissue sarcomas. Clin Cancer Res; 17(7); 1828-38. (C) 2011 AACR.

DOI： 10.1158/1078-0432.CCR-10-2066

Web of Science

researchmap

Treatment of gastric cancer with situs inversus totalis: a case report

Journal of Okayama Medical Association 123 ( 1 ) 45 - 48 2011.4

Stage IVa食道癌の治療方針の検討

田辺俊介, 白川靖博, 井筒将斗, 近藤喜太, 野間和広, 櫻間教文, 宇野太, 永坂岳司, 香川俊輔, 繁光薫, 山辻知樹, 羽井佐実, 松岡順治, 猶本良夫, 藤原俊義

岡山医学会雑誌 123 ( 1 ) 74 - 74 2011.4

食道GISTの切除例2例の経験

井筒将斗, 白川靖博, 田辺俊介, 近藤喜太, 野間和広, 櫻間教文, 宇野太, 永坂岳司, 香川俊輔, 繁光薫, 山辻知樹, 羽井佐実, 松岡順治, 猶本良夫, 藤原俊義

岡山医学会雑誌 123 ( 1 ) 74 - 74 2011.4

KRAS/BRAF/MSI分類による術前からの大腸癌治療戦略構築の提案

永坂岳司, 近藤喜太, 母里淑子, 神原健, 松原長秀, 田中紀章, 三嶋秀行, 藤原俊義

日本大腸肛門病学会雑誌 64 ( 4 ) 266 - 266 2011.4

MicroRNAs as potential target gene in cancer gene therapy of gastrointestinal tumors Reviewed

Hiroshi Tazawa, Shunsuke Kagawa, Toshiyoshi Fujiwara

EXPERT OPINION ON BIOLOGICAL THERAPY 11 ( 2 ) 145 - 155 2011.2

Language：English Publisher：INFORMA HEALTHCARE

Introduction: MicroRNA (miRNA) is a small non-coding RNA, which negatively regulates the expression of many target genes, thereby contributing to the modulation of diverse cell fates. Recent advances in molecular biology have revealed the potential role of miRNAs in tumor initiation, progression and metastasis. Aberrant regulation of miRNAs has been frequently reported in a variety of cancers, including gastrointestinal tumors, suggesting that cancer-related miRNAs are promising as novel biomarkers for tumor diagnosis and are potential target genes for cancer gene therapy against gastrointestinal tumors.
Areas covered: The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21, miR-17-92 cluster) in gastrointestinal tumors. Furthermore, the potential role of miRNAs as novel biomarkers and target genes for cancer gene therapy against gastrointestinal tumors are discussed. We will also outline the potential clinical application of miRNAs for tumor diagnosis and cancer gene therapy against gastrointestinal tumors.
Expert opinion: Exploration of tumor-related miRNAs would provide important opportunities for the development of novel cancer gene therapies aimed at normalizing the critical miRNAs that are deregulated in gastrointestinal tumors.

DOI： 10.1517/14712598.2011.542749

Web of Science

researchmap

右鎖骨下動脈起始異常と反回神経走行異常を伴う食道癌に対する手術経験

二萬英斗, 白川靖博, 渡邉伸一郎, 田辺俊介, 野間和広, 櫻間教文, 繁光薫, 山辻知樹, 羽井佐実, 松岡順治, 猶本良夫, 藤原俊義

岡山医学会雑誌 122 ( 3 ) 281 - 281 2010.12

大腸ポリペクトミー後の横行結腸穿孔症例に対し、腹腔鏡下手術が有効であった一例

伏見卓郎, 近藤喜太, 母里淑子, 永坂岳司, 藤原俊義

岡山医学会雑誌 122 ( 3 ) 281 - 281 2010.12

Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery. Reviewed International journal

Kuroda S, Fujiwara T, Shirakawa Y, Yamasaki Y, Yano S, Uno F, Tazawa H, Hashimoto Y, Watanabe Y, Noma K, Urata Y, Kagawa S, Fujiwara T

Cancer research 70 ( 22 ) 9339 - 9348 2010.11

Language：English Publishing type：Research paper (scientific journal)

The inability to repair DNA double-strand breaks (DSB) leads to radiosensitization, such that ionizing radiation combined with molecular inhibition of cellular DSB processing may greatly affect treatment of human cancer. As a variety of viral products interact with the DNA repair machinery, oncolytic virotherapy may improve the therapeutic window of conventional radiotherapy. Here, we describe the mechanistic basis for synergy of irradiation and OBP-301 (Telomelysin), an attenuated type-5 adenovirus with oncolytic potency that contains the human telomerase reverse transcriptase promoter to regulate viral replication. OBP-301 infection led to E1B55kDa viral protein expression that degraded the complex formed by Mre11, Rad50, and NBS1, which senses DSBs. Subsequently, the phosphorylation of cellular ataxia-telangiectasia mutated protein was inhibited, disrupting the signaling pathway controlling DNA repair. Thus, tumor cells infected with OBP-301 could be rendered sensitive to ionizing radiation. Moreover, by using noninvasive whole-body imaging, we showed that intratumoral injection of OBP-301 followed by regional irradiation induces a substantial antitumor effect, resulting from tumor cell-specific radiosensitization, in an orthotopic human esophageal cancer xenograft model. These results illustrate the potential of combining oncolytic virotherapy and ionizing radiation as a promising strategy in the management of human cancer.

DOI： 10.1158/0008-5472.CAN-10-2333

PubMed

researchmap

　 PREV - NEXT 　

< FUJIWARA Toshiyoshi >

Papers - FUJIWARA Toshiyoshi